solute carrier family 22 member 11Genealiases: OAT4 · hOAT4
Q-omics provides the consensus-scored SLC22A11 profile across patient tissues and cancer cell-line models. SLC22A11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC22A11 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SLC22A11 RNA expression shows 12,463 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where SLC22A11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A11 survival associations across molecular data types. SLC22A11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A11 RNA expression–survival associations across cancer types. High SLC22A11 expression shows unfavorable associations in ACC, THCA and BLCA, but favorable associations in KIRC, BRCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC22A11 RNA expression.
This table summarizes SLC22A11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC22A11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A11 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, BLCA, LIHC and KIRC. The KICH box plot shows higher SLC22A11 RNA expression in normal versus tumor tissue (log2 FC = −3.776, t-test p < 0.001).
This table shows molecular features associated with SLC22A11 in patient tissues and cancer cell lines. In patient samples, SLC22A11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
